Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.
Eva M M StrijbisEline Me CoerverJop MostertZoé Léonie Elise van KempenJoep KillesteinJacynthe ComtoisPavle RepovicJames D BowenGary CutterMarcus Werner KochPublished in: Journal of neurology, neurosurgery, and psychiatry (2023)
Older age is associated with a lower prevalence and degree of focal inflammatory disease activity in treated and untreated RRMS. Our findings inform the design of RCTs, and suggest that patient age should be taken into consideration when deciding on immunomodulatory treatment in RRMS.
Keyphrases
- disease activity
- multiple sclerosis
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- clinical trial
- juvenile idiopathic arthritis
- white matter
- risk factors
- oxidative stress
- randomized controlled trial
- study protocol
- middle aged
- case report
- open label
- replacement therapy